Gastrointestinal Cancers

Courtney Nelson visits with her surgical oncologist Dr. Virgilio George. When Nelson was diagnosed with stage 2 colon cancer, George ended up removing one-third of her colon. Photo by Sarah Pack
Dr. Virgilio George in clinic with a patient.

About the Program

MUSC Hollings Cancer Center is a national leader in treating cancers of the digestive system, including the colon, pancreas, liver, stomach, biliary tree and rectum. We work in close collaboration with the MUSC Health Digestive Disease Center, rated highly for many years for the treatment of these disorders by U.S. News & World Report.

Diagnosis & Treatment

TomoTherapy® Hi-Art® Treatment System

This highly-accurate radiation therapy allows the radiation oncologist to image and treat a patient in the same setting, minimizing toxicity.

CT Colography

A screening alternative to the traditional colonoscopy, the procedure uses a reconstructed CT scan to view the colon.

Endoscopic Ultrasound

Used to stage gastrointestinal, lung and esophageal cancers. Hollings Cancer Center has one of the world’s most renowned endoscopic ultrasound facilities.

Narrow Band Imaging

One of the latest screening techniques uses special light waves to target abnormal areas for biopsy, increasing the accuracy of the biopsy.

Y-90 Microspheres

Hollings Cancer Center is one of only three South Carolina facilities that arterially infuse liver tumors with the radioactive element yttrium-90. We have more experience with this technique than any other program in the state. This treatment offers an outpatient treatment alternative to patients who may have few other available options.

Endoscopic Mucosal Resection

A minimally invasive technique for removing superficial tumors with the use of an endoscope.

Laparoscopic Surgery

Hollings Cancer Center surgical oncologists now use a laparoscope positioned lower in the pelvic area to avoid the colostomies of the past.

Pancreas Chemotherapy Protocol

This leading-edge treatment developed here at Hollings Cancer Center has a 36 percent success rate in making non-operable pancreatic tumors operable.